儿童基本药物目录遴选制度的国外经验启示  

Inspiration from foreign experience of children's essential medicine list system

作　　者：汪倩 刘克军 邱英鹏 张萌[3] 王晓玲[3] 刘永军[1] 肖月 WANG Qian;LIU Ke-jun;QIU Ying-peng;ZHANG Meng;WANG Xiao-ling;LIU Yong-jun;XIAO Yue(School of International Pharmaceutical Business,China Pharmaceutical University,Nanjing JIANGSU 211198,China;Health Development Research Center of National Health Commitee,BEIJING 100044,China;Department of Pharmacy,Beijing Children's Hospital,Capital Medical University/National Center for Children's Health,BEIJING 100045,China)

机构地区：[1]中国药科大学国际医药商学院,江苏南京211198 [2]国家卫生健康委卫生发展研究中心,北京100044 [3]国家儿童医学中心/首都医科大学附属北京儿童医院药学部,北京100045

出　　处：《中国新药与临床杂志》2023年第6期349-354,共6页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：2021年国家卫生健康委药政司发布《国家基本药物目录管理办法(修订草案)》,首次新增儿童用药目录,为保障儿童用药提供了基本制度框架。本研究通过查阅世界卫生组织、南非、印度、泰国、加拿大、澳大利亚等国家政府官网及相关文献,梳理了世界卫生组织(WHO)和部分国家在儿童基本药物目录的典型做法和模式,以期为我国建立健全儿童基本药物目录遴选管理机制提供参考。In 2021,the Department of Drug Policy and Essential Medicine of the National Health Commission of the People's Republic of China issued the Measures for the Administration of the National Essential Medicine List(Revised Draft),which for the first time proposed a new list of medicines for children and provided a basic institutional framework for ensuring the use of children's essential medicines.The typical practices and models in the essential medicines list for children by searching literature were summarized and the official website of relevant departments in World Health Organization(WHO),South Africa,India,Thailand,Canada,Australia and other countries and regions were analyzed in this study,hoping to provide a reference for the construction of the selection and management mechanism of the essential medicines list for children in my country.

关 键 词：儿童 基本药物目录 药品遴选 世界卫生组织 

分 类 号：R95[医药卫生—药学]